Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM Qilian International Holding Group	$12.54 +8.9%	$10.88	$5.26 ▼ $14.78	$1.22B	1.33	26,688 shs	8,093 shs
ETNB 89bio	$7.78 +1.8%	$7.27	$4.16 ▼ $11.84	$1.14B	1.23	1.38 million shs	1.05 million shs
OCUL Ocular Therapeutix	$7.22 +0.7%	$7.41	$4.79 ▼ $11.78	$1.15B	1.51	1.40 million shs	1.64 million shs
PBH Prestige Consumer Healthcare	$89.24 +2.4%	$83.25	$62.35 ▼ $90.04	$4.42B	0.44	295,808 shs	374,113 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM Qilian International Holding Group	-0.26%	+1.95%	+9.82%	+12.06%	+1,151,999,900.00%
ETNB 89bio	-6.83%	-2.24%	+26.28%	-27.72%	-16.96%
OCUL Ocular Therapeutix	+3.46%	-3.72%	-4.78%	-1.51%	+13.99%
PBH Prestige Consumer Healthcare	+1.49%	+0.26%	+7.67%	+1.74%	+31.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGM Qilian International Holding Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETNB 89bio	3.0198 of 5 stars	4.5	1.0	0.0	0.0	4.0	0.8	0.6
OCUL Ocular Therapeutix	4.07 of 5 stars	3.4	3.0	0.0	4.1	2.6	2.5	0.0
PBH Prestige Consumer Healthcare	3.7622 of 5 stars	1.3	3.0	1.7	3.5	2.8	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM Qilian International Holding Group	0.00	N/A	N/A	N/A
ETNB 89bio	3.00	Buy	$26.43	239.70% Upside
OCUL Ocular Therapeutix	2.88	Moderate Buy	$16.25	125.07% Upside
PBH Prestige Consumer Healthcare	2.50	Moderate Buy	$93.33	4.59% Upside

Current Analyst Ratings Breakdown

Latest PBH, ETNB, BGM, and OCUL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/10/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/8/2025	PBH Prestige Consumer Healthcare	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/30/2025	ETNB 89bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/24/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
4/8/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
4/8/2025	OCUL Ocular Therapeutix	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/22/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
3/21/2025	PBH Prestige Consumer Healthcare	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$96.00 ➝ $97.00
3/18/2025	OCUL Ocular Therapeutix	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$17.00

(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM Qilian International Holding Group	$25.10M	48.58	N/A	N/A	$6.10 per share	2.06
ETNB 89bio	N/A	N/A	N/A	N/A	$5.75 per share	N/A
OCUL Ocular Therapeutix	$59.65M	19.28	N/A	N/A	$0.79 per share	9.14
PBH Prestige Consumer Healthcare	$1.14B	3.89	$5.24 per share	17.03	$36.10 per share	2.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM Qilian International Holding Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ETNB 89bio	-$142.19M	-$3.38	N/A	N/A	N/A	N/A	-59.58%	-52.21%	8/4/2025 (Estimated)
OCUL Ocular Therapeutix	-$80.74M	-$1.15	N/A	N/A	N/A	-283.74%	-45.18%	-30.87%	N/A
PBH Prestige Consumer Healthcare	$209.34M	$4.29	20.90	18.75	2.69	19.13%	12.36%	6.39%	N/A

Latest PBH, ETNB, BGM, and OCUL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q4 2025	PBH Prestige Consumer Healthcare	$1.30	$1.32	+$0.02	$1.00	$289.36 million	$296.52 million
5/1/2025	Q1 2025	ETNB 89bio	-$0.50	-$0.49	+$0.01	-$0.49	N/A	N/A
3/6/2025	Q4 2024	ETNB 89bio	-$0.60	-$1.02	-$0.42	-$1.02	N/A	N/A
3/3/2025	Q4 2024	OCUL Ocular Therapeutix	-$0.24	-$0.29	-$0.05	-$0.29	$16.89 million	$17.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM Qilian International Holding Group	N/A	N/A	N/A	N/A	N/A
ETNB 89bio	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	$1.90	2.13%	N/A	44.29%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM Qilian International Holding Group	N/A	3.39	2.82
ETNB 89bio	0.09	11.66	11.66
OCUL Ocular Therapeutix	0.19	13.01	12.94
PBH Prestige Consumer Healthcare	0.56	3.68	2.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM Qilian International Holding Group	N/A
ETNB 89bio	N/A
OCUL Ocular Therapeutix	59.21%
PBH Prestige Consumer Healthcare	99.95%

Insider Ownership

Company	Insider Ownership
BGM Qilian International Holding Group	58.66%
ETNB 89bio	2.60%
OCUL Ocular Therapeutix	3.50%
PBH Prestige Consumer Healthcare	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM Qilian International Holding Group	298	97.22 million	2.48 million	N/A
ETNB 89bio	40	145.98 million	103.15 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	151.71 million	Optionable
PBH Prestige Consumer Healthcare	540	49.54 million	48.75 million	Optionable

PBH, ETNB, BGM, and OCUL Headlines

Recent News About These Companies

PBH vs. ESLOY: Which Stock Should Value Investors Buy Now?

May 14 at 12:45 PM | zacks.com

Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase

May 13 at 4:52 PM | finance.yahoo.com

Equities Analysts Set Expectations for PBH Q1 Earnings

May 13 at 3:45 AM | americanbankingnews.com

Susquehanna International Group LLP Increases Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

May 13 at 3:39 AM | marketbeat.com

Q1 Earnings Forecast for PBH Issued By William Blair

May 13 at 3:32 AM | marketbeat.com

Prestige Consumer Healthcare (NYSE:PBH) Posts Earnings Results, Beats Expectations By $0.02 EPS

May 12, 2025 | marketbeat.com

BNP Paribas Financial Markets Purchases 186,524 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

May 12, 2025 | marketbeat.com

Prestige Consumer Healthcare (NYSE:PBH) Upgraded to "Hold" at Royal Bank of Canada

May 11, 2025 | marketbeat.com

Prestige Consumer Healthcare Inc. (PBH) Q4 2025 Earnings Call Transcript

May 11, 2025 | seekingalpha.com

Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Royal Bank of Canada to "Hold" Rating

May 11, 2025 | americanbankingnews.com

Prestige Consumer Healthcare (NYSE:PBH) Issues FY 2026 Earnings Guidance

May 10, 2025 | marketbeat.com

Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Rating of "Moderate Buy" by Analysts

May 10, 2025 | marketbeat.com

Prestige Consumer Healthcare Inc (PBH) Q4 2025: Everything You Need To Know Ahead Of Earnings

May 9, 2025 | finance.yahoo.com

Prestige Consumer Healthcare Inc (PBH) Q4 2025 Earnings Call Highlights: Record Revenue and ...

May 9, 2025 | finance.yahoo.com

Northern Trust Corp Grows Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

May 9, 2025 | marketbeat.com

Prestige Consumer Healthcare (PBH) Tops Q4 Earnings and Revenue Estimates

May 8, 2025 | zacks.com

UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

May 8, 2025 | globenewswire.com

Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

May 8, 2025 | globenewswire.com

Tudor Investment Corp ET AL Acquires Shares of 16,836 Prestige Consumer Healthcare Inc. (NYSE:PBH)

May 8, 2025 | marketbeat.com

Insights Into Prestige Consumer Healthcare (PBH) Q4: Wall Street Projections for Key Metrics

May 7, 2025 | msn.com

Aristotle Capital Boston LLC Sells 64,071 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

May 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH, ETNB, BGM, and OCUL Company Descriptions

Qilian International Holding Group NASDAQ:BGM

$12.54 +1.02 (+8.85%)

Closing price 03:59 PM Eastern

Extended Trading

$11.93 -0.61 (-4.86%)

As of 07:46 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

89bio NASDAQ:ETNB

$7.78 +0.14 (+1.83%)

Closing price 04:00 PM Eastern

Extended Trading

$7.90 +0.12 (+1.54%)

As of 06:55 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Ocular Therapeutix NASDAQ:OCUL

$7.22 +0.05 (+0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$7.21 -0.01 (-0.19%)

As of 07:57 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Prestige Consumer Healthcare NYSE:PBH

$89.24 +2.13 (+2.45%)

Closing price 03:59 PM Eastern

Extended Trading

$89.13 -0.11 (-0.12%)

As of 05:49 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time